Compare Eli Lilly And Co (LLY) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Phillips 66 — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Phillips 66 trades at $278.18 (market cap $112.36B). The key difference: Eli Lilly And Co is far larger — about 9.3× Phillips 66's market cap, and Phillips 66 pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Phillips 66 for 62 Days on average.
| LLY | PSX | |
|---|---|---|
Market Cap | $1.04T | $112.36B |
Volume | 3,064,878 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $1.28K | $281.60 |
52-Week Low | $799.57 | $126.76 |
Typical Hold Time | 93 Days | 62 Days |
Enterprise Value | $1.09T | $128.83B |
Dividend Yield | 0.59% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Phillips 66 (PSX) trades at $281.60, up 3.67% over the past 24 hours and near its 52-week high, supported by bullish technical indicators and strong earnings beats in recent quarters. The company's fundamentals show solid profitability with a 4.66% net income margin and 24.02% ROE, while valuation ratios like a P/E of 16.07 and P/S of 0.75 appear reasonable. Recent news highlights structural strength in refining margins and AI-driven operational improvements.
The outlook for PSX is positive, driven by elevated refining crack spreads and debt-reduction progress, but risks include volatile energy prices and potential policy impacts on diesel exports. Analyst consensus leans bullish with a $279 price target, offering moderate upside from current levels amid robust institutional sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
